Global Rheumatic Disorders Drugs Market Grow at (CAGR) of 4.46% to $80.04 billion in 2024

Global Rheumatic Disorders Drugs Market to 2024 research report covers key diseases of rheumatic disorders, market size, therapy area overview, etiology, Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation and key marketed products.

Pune, India - February 12, 2019 /MarketersMedia/ —

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry research report added to ReportsnReports online database.
The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

Get Discount on Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854866

This report covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

The market size for rheumatic disorder therapeutics was $58.97 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 4.46% to $80.04 billion in 2024.

Scope

- How is the rheumatic disorders market landscape expected to change?
- Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
- Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
- Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
- The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
- What types of companies are involved in the rheumatic disorder therapy area?
- Will the current market leaders retain their dominance over the forecast period?
- How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to Buy:
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the Rheumatic Disorder Drug Market
- Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
- Identify which two drug classes will see particularly strong market growth over the forecast period
- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
- Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals

Direct Purchase of Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854866

Table of Contents:
1. Introduction
2. Key Marketed Products
3. Pipeline Landscape Assessment
4. Multi-scenario Market Forecast to 2024
5. Company Analysis and Positioning
6. Strategic Consolidations
7. Appendix

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854866-global-rheumatic-disorders-drugs-market-to-2024-increased-uptake-of-il-inhibitors-and-jak-inhibitors-to-drive-growth-as-tnf-inhibitors-face-patent-expiry.html

Source URL: https://marketersmedia.com/global-rheumatic-disorders-drugs-market-grow-at-cagr-of-446-to-8004-billion-in-2024/481750

Source: MarketersMedia

Release ID: 481750

Latest News

China telecom giant Huawei hints US pressure hurting sales

Jun 19, 2019

SHANGHAI — Huawei's chief strategist said Tuesday the company would have become the world's number one smartphone maker by the year's end if not for "unexpected" circumstances — a hint that pressure from the U.S. may be hurting its sales. The comment by Shao Yang at the Consumer Electronics Show in Shanghai comes as Washington intensifies pressure on other countries to exclude Huawei Technologies from next-generation, or 5G, telecom networks where it actually is considered an industry leader. "If we had not encountered anything unexpected, we would have become number one in the world by the fourth quarter," Huawei's chief...

Australian PM: WTO needs mending to keep up with the times

Jun 19, 2019

SINGAPORE — Australian Prime Minister Scott Morrison said Friday that the World Trade Organization needs mending to keep up with the times. Morrison said many leaders attending the Group of 20 summit in Osaka later this month share the view. "There is a strong consensus about the need to modernize the WTO and its rules," he said. "We need to mend it, we don't need to break it, and mending it requires a lot of partnership," he added. "Just now it's the technical practical things that need to get done." Morrison, who spoke at a lunch organized by the Australian...

China says list of 'unreliable' foreign firms coming soon

Jun 19, 2019

BEIJING — China's Commerce Ministry will release a list of "unreliable" foreign companies in the near future, a spokesman said Thursday, without giving a specific date. The decision to create the list, announced last week, is widely seen as a response to a U.S. decision to put Huawei Technologies on a blacklist for alleged theft of intellectual property and evasion of Iran sanctions. Chinese Commerce Ministry spokesman Gao Feng told reporters at a weekly briefing that the process of drawing up the list was underway. He said no particular company or industry is being targeted. "Companies that abide by Chinese...

UN agencies urge stronger efforts to stop illegal fishing

Jun 19, 2019

BANGKOK — Major United Nations agencies are urging key fishing nations to join efforts to fight illegal, unreported and unregulated fishing. The U.N. Food and Agricultural Organization and other groups made the call at a conference in Bangkok on Wednesday focused on helping protect fisheries and those working in the industry. Thailand is the world's biggest importer of tuna. It has one of the seven state-of-the-art centers in the region monitoring fishing vessels in real time to help control access to regional ports and curb illegal fishing. The centers are helping enforce the Port State Measures Agreement, which aims to...

China issues travel alerts, slams US 'interference'

Jun 19, 2019

BEIJING — China issued a pair of travel warnings for the U.S. on Tuesday and slammed what it called "interference" in its internal affairs. Foreign Ministry spokesman Geng Shuang accused the U.S. of acting in bad faith in trade negotiations and said any attempts to interfere or undermine China's stability would be "doomed to fail." The volleys of criticism between the two largest economies leave them further than ever from resolving their standoff over U.S. complaints that Beijing resorts to unfair trade practices and unscrupulous methods to obtain advanced technologies. The Chinese comments followed a statement from the U.S. Trade...

Sign up now!